Fig. 4: OV-αCD47-G1 is effective for locoregional delivery of the anti-CD47 antibody, while systemic administration of αCD47-G1 is not effective.
a Experimental timeline for in vivo studies using an orthotopic model of human GBM. Experiment details are provided in the main text. Group 1, saline; Group 2, OV-Q1; Group 3, a combination of OV-Q1 plus i.p. administration of αCD47-G1; and Group 4, OV-αCD47-G1. After tumor implantation, Groups 2, 3 and 4 received intracranial injection of oHSV (OV-Q1 or OV-αCD47-G1) at a dose of 2 × 105 PFU per mouse on day 21. Group 1 received saline as control. On day 22, Group 3 received i.p. injection of purified αCD47-G1 at the dose of 150 µg per mouse. Groups 1, 2, and 4 received i.p. injection of saline as control. All mice were euthanized on day 23 for blood and brain harvesting. b The concentration of αCD47-G1 in plasma measured by ELISA in mice from different treatments. One-way ANOVA with P values corrected for multiple comparisons by the Bonferroni test (n = 3 animals). c, d Slides from the brain tissues isolated from experimental mice were subjected to H&E and immunohistochemical staining, the latter with anti-HSV, anti-human Fc, which identifies IgG, anti-CD11b or anti-NKp46 antibodies. Images with high and low magnifications are shown in (c) and (d), respectively. The boxed images in (d) are shown in higher power in (c). Data presented are representative of one (c, d) or three (b) mice of at least three mice in total with similar data. Data in (b) are presented as mean values ± SD.
